Glucosylceramidase Pipeline Review and Drug Development by Companies Analyzed in H2 2017


Published on : Nov 10, 2017

Albany, New York, November 10, 2017: Recently, Market Research Hub (MRH) included an in-depth and fact-based research publication titled “Glucosylceramidase (Acid Beta Glucosidase or Alglucerase or D Glucosyl N Acylsphingosine Glucohydrolase or Beta Glucocerebrosidase or Imiglucerase or GBA or EC 3.2.1.45)-Pipeline Review, H2 2017” in its extensive research repository. This report publication portrays a comprehensive intelligence on the therapeutics targeted for Glucosylceramidase along with complete analysis on stage of development, various indications, route of administration, mechanism of action as well as molecule type.

In the first part, the study presents a brief introduction on glucosylceramidase. It mainly belongs to the family of hydrolases that catalyzes the hydrolysis of the glycolipid, glucocerebroside, to glucose and ceramide as part of the normal degradation pathway for membrane lipids. Insufficiency of this enzyme leads to unusually high concentrations of glucosylceramide in the brain in GAUCHER DISEASE. An analysis of the descriptive pharmacological action of therapeutics, along with complete history and latest information through press releases and latest news releases is offered to the readers.

Moving further, the research finds that pipeline target constitutes close to 11 molecules. Out of which around 8 molecules are developed by companies and remaining by the universities/institutes. Currently, The molecules developed by companies in Phase II, Phase I, Preclinical and Discovery stages are 1, 2, 4 and 1 respectively. Apart from that report covers products from therapy areas Genetic Disorders and Central Nervous System which include indications Gaucher Disease, Parkinsons Disease, Gaucher Disease Type I, Gaucher Disease Type III and Neurodegenerative Diseases.

Why invest in this Report?

Readers can expect comprehensive information on the current stage of these molecules, and factors for gaining approval. The report has been compiled after consulting experts in the concerned fields. Repositories of information have been scoured for thorough secondary research. Readers can gain a wealth of information on the recent and anticipated developments in this field. This report also features descriptive drug profiles for the pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

Key Competitor Analysis

This research publication also includes analysis on key players dealing with the development of therapeutics associated with Glucosylceramidase along with developments taking into consideration all dormant or active projects in this section. The data is garnered from SEC filings, company websites, proprietary databases, university websites, conferences, registries of clinical trials, press releases as well as investor presentations. Key companies profiled in this study include Protalix BioTherapeutics Inc., JCR Pharmaceuticals Co Ltd and Pharming Group NV.

Request a Sample with TOC in a PDF format : https://www.marketresearchhub.com/enquiry.php?type=S&repid=1361337

About Market Research Hub

Market Research Hub (MRH) is a next-generation reseller of research reports and analysis. MRH’s expansive collection of market research reports has been carefully curated to help key personnel and decision makers across industry verticals to clearly visualize their operating environment and take strategic steps.

MRH functions as an integrated platform for the following products and services: Objective and sound market forecasts, qualitative and quantitative analysis, incisive insight into defining industry trends, and market share estimates. Our reputation lies in delivering value and world-class capabilities to our clients.

Research Assistance

For Enquiries, Call :

+1-800-998-4852US Toll Free

Email : sales@marketresearchhub.com

Back To Top